Safety, efficacy, and dose response of the maturation inhibitor GSK3532795 (formerly known as BMS-955176) plus tenofovir/emtricitabine once daily in treatment-naive HIV-1-infected adults: Week 24 primary analysis from a randomized Phase IIb trial

GSK3532795 (formerly known as BMS-955176) is a second-generation maturation inhibitor targeting a specific Gag cleavage site between capsid p24 and spacer peptide 1 of HIV-1. Study 205891 (previously AI468038) investigated the efficacy, safety, and dose response of GSK3532795 in treatment-naive, HIV...

Descripción completa

Detalles Bibliográficos
Autores principales: Morales-Ramirez, Javier, Bogner, Johannes R., Molina, Jean-Michel, Lombaard, Johan, Dicker, Ira B., Stock, David A., DeGrosky, Michelle, Gartland, Margaret, Pene Dumitrescu, Teodora, Min, Sherene, Llamoso, Cyril, Joshi, Samit R., Lataillade, Max
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6198970/
https://www.ncbi.nlm.nih.gov/pubmed/30352054
http://dx.doi.org/10.1371/journal.pone.0205368

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6198970/
https://www.ncbi.nlm.nih.gov/pubmed/30352054
http://dx.doi.org/10.1371/journal.pone.0205368

Ejemplares similares